London-based digital health startup, Evaro, has successfully raised $1.5 million in Seed funding, marking a significant milestone in its mission to transform healthcare accessibility. The funding round, spearheaded by Cornerstone VC and Exceptional Ventures, witnessed participation from Catalisi’s investment arm, Syndicate Room, and the University of East Anglia.
Founded in 2018 by Dr. Thuria Wenbar, an emergency doctor, and software developer, along with Dr. Oskar Wendowski, a pharmacist researcher, Evaro has been making strides in addressing the growing demand for streamlined healthcare services. Recognizing that a substantial percentage of A&E consultations and GP appointments involve minor health conditions, the duo set out to revolutionize the healthcare landscape.
Evaro’s innovative approach involves leveraging artificial intelligence and machine learning models, trained on a vast dataset of 13.5 million patient records. The company provides access to AI-driven asynchronous consultations and private prescription medication, ensuring a seamless and secure healthcare experience. Furthermore, Evaro adheres to a stringent regulatory-compliant patient safety process, incorporating mechanisms to detect answer manipulation and scrutinizing drug orders for safe dosages and quantities. Notably, the platform notifies GPs when necessary, reinforcing a collaborative healthcare ecosystem.
The recent funding injection will propel Evaro’s expansion into the B2B market, offering a plug-and-play product. This novel solution enables consumer brands to integrate managed medication prescription services into their offerings. Evaro’s medication catalogue is set to grow from 200 to 2,000 treatments, encompassing 70% of minor health issues typically addressed by NHS doctors.
In line with its mission, Evaro seeks to alleviate the strain on the National Health Service (NHS) by acquiring its Care Quality Commission (CQC) license. This strategic move aims to enable more comprehensive patient care, encompassing diagnosis and therapy initiation.
Dr. Wenbar, CEO of Evaro, highlighted the urgency of their mission, stating, “The NHS is in crisis: you can now wait up to four weeks for a GP appointment, which is made worse by funding cuts and staff shortages.” The digital clinics established by Evaro not only provide faster treatments for minor health issues but also present a commercial opportunity for prominent brands to venture into the digital health space seamlessly.
Dr. Wendowski emphasized the scalability of their initiative, noting, “We’re already helping 350,000 people access healthcare as easily and securely as they access online banking. We now want to scale this.” Evaro’s B2B strategy aims to empower brands in sectors such as cosmetics, sexual health, and travel to navigate the digital health landscape effortlessly.
Rodney Appiah, Founder and Managing Director at Cornerstone VC, expressed enthusiasm for Evaro’s vision, emphasizing the potential to democratize access to healthcare. “Imagine a world where your favorite cosmetics company can offer prescriptions for acne, eczema, and psoriasis,” he said.
Evaro’s journey is poised to redefine safety and efficiency standards in online healthcare while addressing the evolving needs of patients and enhancing collaboration between healthcare providers and consumer brands.